Regeneron, the maker of the late REGEN-COV, has two antibody treatments in Phase 1 trials, according to a spokesperson; AstraZeneca, Evusheld’s parent, also has replacements in development ...

Regeneron Pharmaceuticals and AstraZeneca, makers of monoclonal antibody cocktails used as treatment for many coronavirus patients who have not been vaccinated, announced contrasting data Thursday ...

Regeneron warned its popular antibody cocktail used to treat high-risk cases of COVID-19 may not be as effective against the new Omicron variant. The New York-based pharmaceutical company said ...

The high earnings come after the pharmaceutical giant secured an agreement with the federal government to provide an extra 1.4 million doses of its antibody cocktail. Roughly 300,000 doses were ...

Regeneron Pharmaceuticals said Tuesday that its antibody cocktail, which is used widely to treat COVID-19 patients, may be less effective against the Omicron variant.

Here are the details from the late-stage trials. The company found that its antibody cocktail reduced the risk of participants getting infected by 81.6%. This protection lasted between 2 and 8 months.

Regeneron’s antibody cocktail cut the risk of contracting COVID-19 by 81.6 percent in the two to eight months after the cocktail’s administration, the pharmaceutical company announced on Monday.

Coronavirus Regeneron reports COVID-19 antibody cocktail reduced infection risk by 82% for 8 months — so far Regeneron touted the treatment as a promising alternative to vaccination ...

SAN FRANCISCO (KRON) — Phase 3 trial results by biotech company Regeneron showed its new drug provides long-term protection against COVID. A single dose of the antibody cocktail reduced COVID ...

A single dose of Regeneron’s antibody cocktail—administered via four injections—cut the risk of contracting Covid-19 by 81.6% up to eight months after it’s given, the New York-based ...

SAN FRANCISCO (KRON) — Phase 3 trial results by biotech company Regeneron showed its new drug provides long-term protection against COVID-19. A single dose of the antibody cocktail reduced the ...

SAN FRANCISCO (KRON) — Phase 3 trial results by biotech company Regeneron showed its new drug provides long-term protection against COVID-19. A single-dose of the antibody cocktail reduced the ...